Wall Street Analysts Are Bullish on Top Healthcare Picks

view original post

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aptose Biosciences (APTOResearch Report), Syndax Pharmaceuticals (SNDXResearch Report) and Delcath Systems (DCTHResearch Report) with bullish sentiments.

Aptose Biosciences (APTO)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Aptose Biosciences, with a price target of $23.00. The company’s shares closed last Tuesday at $1.60, close to its 52-week low of $1.36.

According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 17.1% and a 46.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Genenta Science SpA Sponsored ADR, Bioline RX Ltd Sponsored ADR, and Cadrenal Therapeutics, Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aptose Biosciences with a $14.00 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Syndax Pharmaceuticals (SNDX)

In a report released today, Edward White from H.C. Wainwright reiterated a Buy rating on Syndax Pharmaceuticals, with a price target of $41.00. The company’s shares closed last Tuesday at $21.44.

According to TipRanks.com, White has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -9.2% and a 33.8% success rate. White covers the Healthcare sector, focusing on stocks such as 60 Degrees Pharmaceuticals, Inc., Karyopharm Therapeutics, and Inhibikase Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Syndax Pharmaceuticals with a $34.00 average price target, implying a 50.0% upside from current levels. In a report issued on March 20, J.P. Morgan also maintained a Buy rating on the stock with a $34.00 price target.

Delcath Systems (DCTH)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Delcath Systems, with a price target of $20.00. The company’s shares closed last Tuesday at $4.61.

According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of 1.8% and a 34.9% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as ImmunoPrecise Antibodies, Janux Therapeutics Inc, and ALX Oncology Holdings.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Delcath Systems with a $18.00 average price target, which is a 293.9% upside from current levels. In a report released yesterday, BTIG also reiterated a Buy rating on the stock with a $16.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on APTO: